Gene therapy developer Corlieve, which utilises University of Bordeaux, Aix Marseille University, CNRS and Inserm research, is set to be acquired by peer QniQure for about $55m.

Corlieve Therapeutics, a France-based gene therapy developer spun out of University of Bordeaux, Aix Marseille University and research institutes Inserm and CNRS, is set to be acquired by fellow gene therapy specialist UniQure for €46.3m ($55.1m).
Founded in 2019, Corlieve is developing gene therapies for severe neurological disorders. Its lead therapy programme, AMT-260, is being developed to treat drug-resistant temporal lobe epilepsy.
The deal features additional payments to Corlieve shareholders including $52m for the advancement of AMT-260 through phase 1/2 development.  They would also receive $191m should the drug cabdidtae achieve phase 3 development milestones and secure approval for use in the US and European Union.
Corlieve received an undisclosed amount in a seed round co-led by Kurma Partners and Idinvest and backed by Pureos Bioventures in November 2020. Gene therapy developer Regenxbio had taken an equity stake in Corlieve after forming a license and collaboration agreement with the company.